{"id":404810,"date":"2020-12-22T16:08:36","date_gmt":"2020-12-22T21:08:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=404810"},"modified":"2020-12-22T16:08:36","modified_gmt":"2020-12-22T21:08:36","slug":"nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/","title":{"rendered":"Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Friday, January 15, 2021, at 4:00 pm Pacific Time \/ 6:00 pm Central Time<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">REDWOOD CITY, Calif.<\/span>, <span class=\"xn-chron\">Dec. 22, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0Nevro Corp.\u00a0(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced\u00a0it will host and webcast a virtual investor briefing at the 2021 North American Neuromodulation Society (NANS) Virtual Conference on <span class=\"xn-chron\">Friday, January 15, 2021<\/span>, beginning at <span class=\"xn-chron\">4:00 pm PST<\/span> \/ <span class=\"xn-chron\">6:00 pm CST<\/span>.\u00a0 Nevro Chairman, CEO and President <span class=\"xn-person\">D. Keith Grossman<\/span> will host the event and will provide a business update and answer questions from investors about the Company&#8217;s latest developments.\u00a0 Nevro&#8217;s Chief Medical Officer, <span class=\"xn-person\">David Caraway<\/span>, MD, PhD, and Nevro&#8217;s Chief Financial Officer, <span class=\"xn-person\">Rod MacLeod<\/span>, will also participate in the event.\u00a0 \u00a0\u00a0<\/p>\n<p>This investor briefing will take place following the conclusion of the NANS <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3021052-1&amp;h=3404714603&amp;u=https%3A%2F%2Fconference.neuromodulation.org%2Fitem%2F897-plenary-session-i&amp;a=Plenary+Session+1\" rel=\"nofollow noopener noreferrer\">Plenary Session 1<\/a>, which will showcase late-breaking abstracts, including data for the SENZA-Painful Diabetic Neuropathy (PDN) randomized clinical trial (RCT) and a first look at results from the Non-Surgical Refractory Back Pain (NSRBP) RCT.\u00a0 \u00a0\u00a0\u00a0<\/p>\n<p>\n        <b>Painful Diabetic Neuropathy (PDN)<\/b>\n      <\/p>\n<p>Nevro&#8217;s PDN trial is the largest RCT of SCS treatment completed thus far with 216 randomized subjects. The data presented will extend the primary endpoint outcomes presented at NANS in <span class=\"xn-chron\">January 2020<\/span>, highlighting complete 6-month results and analysis of all prespecified secondary endpoints. Additionally, a first look at preliminary 12-month pain relief and preliminary crossover results will be included. Results will be presented by <span class=\"xn-person\">Erika A. Petersen<\/span>, MD, from the <span class=\"xn-org\">University of Arkansas<\/span> for Medical Sciences, Department of Neurosurgery, on <span class=\"xn-chron\">January 15, 2021<\/span>, from <span class=\"xn-chron\">4:53-5:05 pm Central Time<\/span>, at NANS 2021 Late-Breaking Abstract <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3021052-1&amp;h=3404714603&amp;u=https%3A%2F%2Fconference.neuromodulation.org%2Fitem%2F897-plenary-session-i&amp;a=Plenary+Session+1\" rel=\"nofollow noopener noreferrer\">Plenary Session 1<\/a>.<\/p>\n<p>\n        <b>Non-Surgical Refractory Back Pain<\/b>\u00a0<b>(NSRBP)<\/b><\/p>\n<p>Nevro&#8217;s NSRBP data presentation will include 3-month primary endpoint results from this RCT investigating spinal cord stimulation efficacy in Non-Surgical Refractory Back Pain, with 159 randomized subjects from 15 study centers. Results will be presented by Leonardo Kapural, MD, PhD, from <span class=\"xn-org\">Wake Forest University<\/span>, <span class=\"xn-location\">Winston-Salem, NC<\/span>, on <span class=\"xn-chron\">January 15, 2021<\/span>, from <span class=\"xn-chron\">4:17-4:29 pm Central Time<\/span>, at NANS 2021 Late-Breaking Abstract <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3021052-1&amp;h=3404714603&amp;u=https%3A%2F%2Fconference.neuromodulation.org%2Fitem%2F897-plenary-session-i&amp;a=Plenary+Session+1\" rel=\"nofollow noopener noreferrer\">Plenary Session 1<\/a>.<\/p>\n<p>A live webcast of this virtual investor briefing, as well as an archived recording, will be available in the Investors section of Nevro&#8217;s website at\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3021052-1&amp;h=2083248765&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2879534-1%26h%3D4227538825%26u%3Dhttp%253A%252F%252Fwww.nevro.com%252F%26a%3Dwww.nevro.com&amp;a=www.nevro.com\" rel=\"nofollow noopener noreferrer\">www.nevro.com<\/a>.<\/p>\n<p>\n        <b>Internet Posting of Information\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/b>\n      <\/p>\n<p>Nevro routinely posts information that may be important to investors in the &#8220;Investor Relations&#8221; section of its website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3021052-1&amp;h=355940232&amp;u=http%3A%2F%2Fwww.nevro.com%2F&amp;a=www.nevro.com\" rel=\"nofollow noopener noreferrer\">www.nevro.com<\/a>.\u00a0 The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.<\/p>\n<p>\n        <b>About Nevro<\/b>\n      <\/p>\n<p>Headquartered in <span class=\"xn-location\">Redwood City, California<\/span>, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in \u226565% of patients across six peer-reviewed clinical studies. The Senza<sup>\u00ae<\/sup>\u00a0System, Senza II\u2122 System, and the Senza<sup>\u00ae<\/sup>\u00a0Omnia\u2122 System\u00a0are the only SCS systems that deliver Nevro&#8217;s proprietary HF10<sup>\u00ae<\/sup>\u00a0therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.<\/p>\n<p>To learn more about Nevro, connect with us on\u00a0<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3021052-1&amp;h=102133622&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2957666-1%26h%3D3237026080%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fnevro%252F%26a%3DLinkedIn&amp;a=LinkedIn\" rel=\"nofollow noopener noreferrer\">LinkedIn<\/a><\/u>,\u00a0<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3021052-1&amp;h=1303803917&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2957666-1%26h%3D3756300817%26u%3Dhttps%253A%252F%252Ftwitter.com%252Fnevro_hf10%26a%3DTwitter&amp;a=Twitter\" rel=\"nofollow noopener noreferrer\">Twitter<\/a><\/u>,\u00a0<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3021052-1&amp;h=2086993574&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2957666-1%26h%3D233801870%26u%3Dhttps%253A%252F%252Fwww.facebook.com%252FHF10therapy%252F%26a%3DFacebook&amp;a=Facebook\" rel=\"nofollow noopener noreferrer\">Facebook<\/a><\/u>\u00a0and\u00a0<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3021052-1&amp;h=1934178939&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2957666-1%26h%3D464884540%26u%3Dhttps%253A%252F%252Fwww.instagram.com%252Fnevro_hf10%252F%26a%3DInstagram&amp;a=Instagram\" rel=\"nofollow noopener noreferrer\">Instagram<\/a><\/u>.<\/p>\n<p>\n        <b>Investors and Media: <br \/><\/b><br \/>\n        <span class=\"xn-person\">Julie Dewey<\/span>, IRC <br \/>Nevro Corp. <br \/>Vice President, Investor Relations &amp; Corp Communications <br \/>650-433-3247\u00a0 |\u00a0 <a target=\"_blank\" href=\"mailto:julie.dewey@nevro.com\" rel=\"nofollow noopener noreferrer\">julie.dewey@nevro.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder6975\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg\" title=\".\" alt=\".\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF32237&amp;sd=2020-12-22\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference-301197807.html\">http:\/\/www.prnewswire.com\/news-releases\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference-301197807.html<\/a><\/p>\n<p>SOURCE  Nevro Corp.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=SF32237&amp;Transmission_Id=202012221605PR_NEWS_USPR_____SF32237&amp;DateId=20201222\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Friday, January 15, 2021, at 4:00 pm Pacific Time \/ 6:00 pm Central Time PR Newswire REDWOOD CITY, Calif., Dec. 22, 2020 \/PRNewswire\/ &#8212;\u00a0Nevro Corp.\u00a0(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced\u00a0it will host and webcast a virtual investor briefing at the 2021 North American Neuromodulation Society (NANS) Virtual Conference on Friday, January 15, 2021, beginning at 4:00 pm PST \/ 6:00 pm CST.\u00a0 Nevro Chairman, CEO and President D. Keith Grossman will host the event and will provide a business update and answer questions from investors about the Company&#8217;s latest developments.\u00a0 Nevro&#8217;s Chief Medical Officer, David Caraway, MD, PhD, and Nevro&#8217;s Chief Financial Officer, Rod MacLeod, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-404810","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Friday, January 15, 2021, at 4:00 pm Pacific Time \/ 6:00 pm Central Time PR Newswire REDWOOD CITY, Calif., Dec. 22, 2020 \/PRNewswire\/ &#8212;\u00a0Nevro Corp.\u00a0(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced\u00a0it will host and webcast a virtual investor briefing at the 2021 North American Neuromodulation Society (NANS) Virtual Conference on Friday, January 15, 2021, beginning at 4:00 pm PST \/ 6:00 pm CST.\u00a0 Nevro Chairman, CEO and President D. Keith Grossman will host the event and will provide a business update and answer questions from investors about the Company&#8217;s latest developments.\u00a0 Nevro&#8217;s Chief Medical Officer, David Caraway, MD, PhD, and Nevro&#8217;s Chief Financial Officer, Rod MacLeod, &hellip; Continue reading &quot;Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-22T21:08:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference\",\"datePublished\":\"2020-12-22T21:08:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\\\/\"},\"wordCount\":567,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/466682\\\/Nevro_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\\\/\",\"name\":\"Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/466682\\\/Nevro_Logo.jpg\",\"datePublished\":\"2020-12-22T21:08:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/466682\\\/Nevro_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/466682\\\/Nevro_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference - Market Newsdesk","og_description":"Friday, January 15, 2021, at 4:00 pm Pacific Time \/ 6:00 pm Central Time PR Newswire REDWOOD CITY, Calif., Dec. 22, 2020 \/PRNewswire\/ &#8212;\u00a0Nevro Corp.\u00a0(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced\u00a0it will host and webcast a virtual investor briefing at the 2021 North American Neuromodulation Society (NANS) Virtual Conference on Friday, January 15, 2021, beginning at 4:00 pm PST \/ 6:00 pm CST.\u00a0 Nevro Chairman, CEO and President D. Keith Grossman will host the event and will provide a business update and answer questions from investors about the Company&#8217;s latest developments.\u00a0 Nevro&#8217;s Chief Medical Officer, David Caraway, MD, PhD, and Nevro&#8217;s Chief Financial Officer, Rod MacLeod, &hellip; Continue reading \"Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-22T21:08:36+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference","datePublished":"2020-12-22T21:08:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/"},"wordCount":567,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/","name":"Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg","datePublished":"2020-12-22T21:08:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-host-virtual-investor-briefing-at-2021-north-american-neuromodulation-society-nans-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/404810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=404810"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/404810\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=404810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=404810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=404810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}